Moreover, long-term follow-up of the NSABP P-1 study, one of the largest prospective breast cancer prevention trials, has revealed a risk decrease of breast cancer in women with past atypical hyperplasia taking tamoxifen, presumably through the ER [221]. The gene discussed is ESR1; the disease is breast carcinoma.